Transvenous phrenic nerve stimulation improves central sleep apnea, sleep quality, and quality of life regardless of prior positive airway pressure treatment
| العنوان: | Transvenous phrenic nerve stimulation improves central sleep apnea, sleep quality, and quality of life regardless of prior positive airway pressure treatment |
|---|---|
| المؤلفون: | Alan R. Schwartz, Lee R. Goldberg, Timothy I. Morgenthaler, Scott McKane |
| المصدر: | Sleep & Breathing = Schlaf & Atmung |
| بيانات النشر: | Springer Science and Business Media LLC, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Male, medicine.medical_specialty, Central sleep apnea, Neurology, purl.org/pe-repo/ocde/ford#3.02.25 [https], Transvenous phrenic nerve stimulation, Electric Stimulation Therapy, Stimulation, Positive airway pressure, 03 medical and health sciences, 0302 clinical medicine, Quality of life, medicine, Humans, Patient Reported Outcome Measures, Aged, Continuous Positive Airway Pressure, business.industry, Sleep Breathing Physiology and Disorders • Original Article, Epworth Sleepiness Scale, Middle Aged, medicine.disease, Sleep Apnea, Central, Phrenic Nerve, Implantable Neurostimulators, Sleep Quality, 030228 respiratory system, Otorhinolaryngology, purl.org/pe-repo/ocde/ford#3.02.07 [https], Anesthesia, Quality of Life, Female, Neurology (clinical), Implant, business, 030217 neurology & neurosurgery |
| الوصف: | Study objective Positive airway pressure (PAP) therapy for central sleep apnea (CSA) is often poorly tolerated, ineffective, or contraindicated. Transvenous phrenic nerve stimulation (TPNS) offers an alternative, although its impact on previously PAP-treated patients with CSA has not been examined. Methods TPNS responses among PAP-naïve and prior PAP-treated patients from the remedē® System Pivotal Trial were assessed. Of 151, 56 (37%) used PAP therapy before enrolling in the trial. Patients were implanted with a TPNS device and randomized to either active or deferred (control) therapy for 6 months before therapy activation. Apnea-hypopnea index (AHI) and patient-reported outcomes (PRO) were assessed at baseline, and 6 and 12 months following active therapy. Results Patients had moderate-severe CSA at baseline, which was of greater severity and more symptomatic in the PAP-treated vs. PAP-naïve group (median AHI 52/h vs. 38, central apnea index (CAI) 32/h vs. 18, Epworth Sleepiness Scale 13 vs. 10, fatigue severity scale 5.2 vs. 4.5). Twelve months of TPNS decreased AHI to Conclusion Polysomnographic and clinical responses to TPNS were comparable in PAP-naïve and prior PAP-treated CSA patients. TPNS is a viable therapy across a broad spectrum of CSA patients. Trial registration ClinicalTrials.gov Identifier NCT01816776; March 22, 2013 |
| تدمد: | 1522-1709 1520-9512 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ac1609be7fb563209dfd39319b2c863 https://doi.org/10.1007/s11325-021-02335-x |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....2ac1609be7fb563209dfd39319b2c863 |
| قاعدة البيانات: | OpenAIRE |
Find this article in full text from Springer Verlag. | تدمد: | 15221709 15209512 |
|---|